Shares of Intellipharmaceutics International Inc. (IPCI – Snapshot Report) surged significantly after the company announced that the bioequivalence trials on Rexista Oxycodone XR extended release tablets have demonstrated bioequivalence to privately held Purdue Pharma’s Oxycontin extended release tablets.
We note that Rexista Oxycodone XR is Intellipharmaceutics’ non-generic extended release formulation for the management of moderate-to-severe pain when an analgesic is required constantly.
Intellipharmaceutics International (IPCI – Snapshot Report) announced that it has technologically upgraded its Rexista oxycodone development program to prevent overdose when tablets in excess of the prescribed dose are swallowed. Patents pending with the U.S. Patent and Trademark office cover the company’s new platform technology, PODRAS. The abuse-deterrent oxycodone is being developed to treat moderate-to-severe pain in situations requiring long-term use (more…)